Literature DB >> 11371644

T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3.

N A Glavas1, C Ostenson, J B Schaefer, V Vasta, J A Beavo.   

Abstract

Agents that increase intracellular cAMP inhibit the activation and function of T cells and can lead to cell death. Recently, it has been postulated that cAMP inhibits T cell function in large part by acting as a brake on the T cell receptor and costimulatory receptor pathways. Therefore, for full activation of the T cell to occur, this inhibitory influence must be removed. One likely mechanism for accomplishing this is by up-regulation and/or activation of specific cyclic nucleotide phosphodiesterases (PDEs), and such a mechanism for one phosphodiesterase, PDE7A1, has been reported. In this paper, we extend this mechanism to another isozyme variant of the same PDE family, PDE7A3. We also report the full-length sequence of human PDE8A1 and show that it also is induced in response to a combination of T cell receptor and costimulatory receptor pathway activation. However, the time course for induction of PDE8A1 is slower than that of PDE7A1. The basal level measured and, therefore, the apparent fold induction of PDE7A1 mRNA and protein depend in large part on the method of isolation of the T cells. On the other hand, regardless of the isolation method, the basal levels of PDE7A3 and PDE8A1 are very low and fold activation is much higher. Constitutively expressed PDE8A1 and PDE7A3 also have been isolated from a human T cell line, Hut78.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371644      PMCID: PMC33466          DOI: 10.1073/pnas.101131098

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

2.  Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.

Authors:  S H Soderling; S J Bayuga; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

3.  CD3- and CD28-dependent induction of PDE7 required for T cell activation.

Authors:  L Li; C Yee; J A Beavo
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Inhibition of lymphocyte stimulation by cyclic and non-cyclic nucleotides.

Authors:  G Estes; S S Solomon; W L Norton
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

5.  Stimulation of T-cells with OKT3 antibodies increases forskolin binding and cyclic AMP accumulation.

Authors:  A Kvanta; P Gerwins; M Jondal; B B Fredholm
Journal:  Cell Signal       Date:  1990       Impact factor: 4.315

6.  Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.

Authors:  R X Xu; A M Hassell; D Vanderwall; M H Lambert; W D Holmes; M A Luther; W J Rocque; M V Milburn; Y Zhao; H Ke; R T Nolte
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

7.  The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens.

Authors:  M L Baroja; K Lorre; F Van Vaeck; J L Ceuppens
Journal:  Cell Immunol       Date:  1989-04-15       Impact factor: 4.868

8.  Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

Authors:  C D Manning; M Burman; S B Christensen; L B Cieslinski; D M Essayan; M Grous; T J Torphy; M S Barnette
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

9.  Purification of two calcium/calmodulin-dependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatography.

Authors:  R S Hansen; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.

Authors:  L Fawcett; R Baxendale; P Stacey; C McGrouther; I Harrow; S Soderling; J Hetman; J A Beavo; S C Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  26 in total

Review 1.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A.

Authors:  Valeria Vasta; Masami Shimizu-Albergine; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

4.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.

Authors:  S-L Catherine Jin; Marco Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Functional characterization of the human phosphodiesterase 7A1 promoter.

Authors:  Mònica Torras-Llort; Fernando Azorín
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

6.  Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain.

Authors:  Zier Yan; Huanchen Wang; Jiwen Cai; Hengming Ke
Journal:  Protein Expr Purif       Date:  2008-10-19       Impact factor: 1.650

7.  PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.

Authors:  Amanda G Vang; Shlomo Z Ben-Sasson; Hongli Dong; Barbara Kream; Michael P DeNinno; Michelle M Claffey; William Housley; Robert B Clark; Paul M Epstein; Stefan Brocke
Journal:  PLoS One       Date:  2010-08-09       Impact factor: 3.240

8.  Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.

Authors:  John A Meyers; Derrick W Su; Adam Lerner
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

9.  miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA.

Authors:  Bo Huang; Jie Zhao; Zhang Lei; Shiqian Shen; Dong Li; Guan-Xin Shen; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  EMBO Rep       Date:  2008-12-19       Impact factor: 8.807

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.